PD-L1 positive non-small cell lung cancer

PD-L1 positive non-small cell lung cancer is a biomarker-defined subtype of non-small cell lung cancer, a malignancy arising from epithelial cells within the respiratory system

PD-L1 positive non-small cell lung cancer is a biomarker-defined subtype of non-small cell lung cancer, a malignancy arising from epithelial cells within the respiratory system Pathophysiologically, the tumor exploits this immune checkpoint protein to bind PD-1 receptors on cytotoxic T cells, suppressing host antitumor immune responses and facilitating immune evasion

It is characterized by immunohistochemical detection of programmed death-ligand 1 (PD-L1) on the surface of tumor cells or tumor-infiltrating immune cells, commonly quantified using a tumor proportion score

It is characterized by immunohistochemical detection of programmed death-ligand 1 (PD-L1) on the surface of tumor cells or tumor-infiltrating immune cells, commonly quantified using a tumor proportion score

Pathophysiologically, the tumor exploits this immune checkpoint protein to bind PD-1 receptors on cytotoxic T cells, suppressing host antitumor immune responses and facilitating immune evasion

Identification of PD-L1 positivity serves as a predictive biomarker to guide treatment eligibility, typically in advanced or metastatic disease

Identification of PD-L1 positivity serves as a predictive biomarker to guide treatment eligibility, typically in advanced or metastatic disease

Identification of PD-L1 positivity serves as a predictive biomarker to guide treatment eligibility, typically in advanced or metastatic disease